Shenzhen RuiJin Pharmaceutical Co.,Ltd 86-188-06592208 Gavin@hgh-steroid.com
Breast Cancer Female 112809-51-5 Anti Estrogen Steroids

Breast Cancer Female 112809-51-5 Anti Estrogen Steroids

  • High Light

    CGS-20267

    ,

    Letrozole Powder

  • Product name
    Letrozole
  • Other Name
    Femara
  • CAS register number
    112809-51-5
  • Molecular formula
    C17H11N5
  • Molecular weight
    285.3
  • Appearance
    White Powder
  • Usage
    Used As API In Treatment Of Breast Disease.
  • Email
    Gavin@pharmrich.com
  • Place of Origin
    China
  • Brand Name
    RuiiJin
  • Certification
    ISO9001
  • Model Number
    112809-51-5
  • Minimum Order Quantity
    10g
  • Price
    Negotiable
  • Packaging Details
    Disguised package or according to your requirement
  • Delivery Time
    Within 24hours after payment
  • Payment Terms
    Western union and moneygram,Bank transfer,Bitcoin, T/T
  • Supply Ability
    3000t/month

Breast Cancer Female 112809-51-5 Anti Estrogen Steroids

Female Anti Estrogen Steroids Letrozole 112809-51-5 Powder For Breast Cancer

 

Quick Detail:

 

 

  • CAS : 112809-51-5

  • Synonyms:FEMARA;CGS-20267;LETROZOL;LETROZOLE;LetrozoleUsp28;Letrozole99%;CGS-20267, Femara

  • Purity:99%

  • Appearance:White or light yellow crystal

  • Molecular Formula: C17H11N5

  • Molecular Weight: 285.31

  • Anti Estrogen Bodybuilding Steroids Letrozole Femara White Powder CAS 112809-51-5

  •  

  • Usage: Used as API in Treatment of breast disease.

  • Recommended dose of Femara is one 2.5 mg tablet administered once a day, without regard to meals.

Letrozole lowers estrogen levels in postmenopausal women, which may slow the growth of certain types of breast tumors that need estrogen to grow in the body.

 

Letrozole is used to treat breast cancer in postmenopausal women.

 

How to Store?
Out of reach of children
Keep it in the container tightly closed
Store it at room temperature and away from excess heat and moisture
Throw away any medication that is outdated or no longer needed

 

How Letrozole works:

 

Letrozole lowers the levels of the female sex hormone oestrogen in the body. Oestrogen stimulates some breast cancers to grow. These breast cancers are called hormone sensitive or hormone receptor positive. Letrozole can stop or slow the growth of these cancers.

 

Letrozole only works in women who have had their menopause.

 

After the menopause, women don't produce oestrogen from their ovaries. But they still produce a small amount by using an enzyme called aromatase which turns other sex hormones called androgens into oestrogen. This change happens mainly in fatty tissue, muscle and the skin. Letrozole is a type of drug called an aromatase inhibitor. It blocks aromatase so that it can't change androgens into oestrogen.

 

 

 

Recipes:

 

200ml @ 5 mg/ml

1 gram of Letrozole powder

1 beaker suitable for holding the volume of liquids

19.9 ml of PEG 300

179.1 ml of 190 Proof Grain Alcohol

 

 

 

Anti-Estrogens Series Product :

 

Anti-estrogen Series

Tamoxifen Citrate

CAS No.: 563.64

Clomifene Citrate

CAS No.: 50-41-9

Toremifene Citrate

CAS No.: 89778-27-8

Exemestane

CAS No.: 107868-30-4

Anastrozole

CAS No.: 120511-73-1

Letrozole

CAS No.: 112809-51-5

Fulvestrant

CAS No.: 129453-61-8

 

 

Femara (Letrozole) Side effects :

 

Common Side Effects:

Bone And Joint Pain

Fatigue

Dizziness

Drowsiness

Higher Cholesterol

Hot Flashes

Weight Gain

Nausea

Vomiting

 

 

Other Side Effects:

Swelling Of Hands, Feet, Ankles, Or Lower Legs

Loss Of Appetite

Constipation

Diarrhea

Difficulty Sleeping

Vaginal Bleeding

Breast Pain

Fever

Cough

Dry Skin

Rash

 

 

Specification:

 

Letrozole Femara
Tests Specifications Results
Appearance White or off-white crystaline powder

White

Crystalline powder

Solubility

 

Soluble in Chloroform;

Soluble in ethanol when heated

Conform
ldentification

(1)Maximum absorption in wavelength of 240 nm

Minimum absorption in wavelength of 215 nm

Conform

Conform

(2)Infrared spectrum should be in accordance the dominant peak of contrast In accordance with the dominant peak of contrast
Melting points 182℃-184℃ 182℃
Related substances ≤0.5% 0.3%
Single impurity ≤0.3% 0.2%
Loss on drying ≤1.0% 0.8%

[Assay]C17H11N5

(On anhydrous basis)

≥98.0% 99.2%
Conclusion Conforms Specifications of Enterprise Standard.